Chiesi Farmaceutici has submitted an MAA to the European Medicines Agency (EMA) for its extra-fine ICS/LABA/LAMA combination inhaler for the treatment of COPD. The submission is the first for a triple combination inhaler.
Chiesi VP and R&D Director Paolo Chiesi said, “We are proud of this key milestone in our R&D program. If approved, this therapeutic option will, on one hand, mark genuine progress in the management of COPD patients, to reduce the impact of their pathological condition, both on their health and on their quality of life. On the other hand, its clinical outcome will reduce the direct and indirect costs associated with patient hospitalization.”
Read the Chiesi press release.
